Total mesorectal excision for rectal cancer in an unselected population: quality assessment in a low volume center by Ferenschild, Floris T. J. et al.
ORIGINAL ARTICLE
Total mesorectal excision for rectal cancer in an unselected
population: quality assessment in a low volume center
Floris T. J. Ferenschild & Imro Dawson &
Johannes H. W. de Wilt & Eelco J. R. de Graaf &
Richard P. R. Groenendijk & Geert W. M. Tetteroo
Accepted: 13 May 2009 /Published online: 2 June 2009
# The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract
Objective The aim of this study was to review the results
and long-term outcome after total mesorectal excision
(TME) for adenocarcinoma of the rectum in an unselected
population in a community teaching hospital.
Materials and methods Between 1996 and 2003, 210
patients with rectal cancer were identified in our prospec-
tive database, containing patient characteristics, radiother-
apy plans, operation notes, histopathological reports, and
follow-up details. An evaluation of prognostic factors for
local recurrence, distant metastases, and overall survival
was performed.
Results The mean age at diagnosis was 69 years (range 40–
91 years). A total of 145 patients were treated by anterior
rectal resection; 65 patients had to undergo an abdomino-
perineal resection (APR). Anastomotic leakage rate was
5%. Postoperative mortality was 3%. After a median
follow-up of 3.6 years, the local recurrence-free rate in
patients with microscopically complete resections was 91%.
The 5-year overall survival rate was 58%. An increased
serum carcinoembryonic antigen, an APR, positive lymph
nodes, and an incomplete resection all significantly influ-
enced the 5-year overall survival and local recurrence rate.
In a multivariate analysis, age was the most important
prognostic factor for overall survival.
Conclusions Patients with rectal cancer can safely be
treated with TME in a community teaching hospital and
leads to a good overall survival and an excellent local
control. In patients aged above 80, treatment-related
mortality is an important competitive risk factor, which
obscures the positive effect of modern rectal cancer
treatment.
Keywords TME.Localrecurrence.Rectalcancer.
Carcinoma.Radiotherapy.CEA
Abbreviations
TME total mesorectal excision
LAR low anterior resection
APR abdominoperineal resection
TEM transanal endoscopic microsurgery
EBRT external beam radiation therapy
CEA carcinoembryonic antigen
CT computed tomography
MRI magnetic resonance imaging
AJCC American Joint Committee of Cancer
TNM tumor node metastases
Introduction
The ultimate goal in the treatment of rectal cancer is to
maximize local control and to improve overall long-term
survival. Local recurrence is a serious problem in the
treatment of rectal cancer, since it causes disabling
symptoms and is difficult to treat; besides, it is thought to
be an important factor in overall long-term survival. After
conventional surgery, a high incidence of local recurrence
of up to 40% was reported [1, 2]. Heald described a new
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(TME)techniqueinwhichtheentiremesorectumisenveloped
andresected[3–5].The introductionofthissurgical technique
resulted in a local recurrence rate of <10% in specialized
centers. It was recognized that the involvement of the
circumferential margin by tumor cells is predictive for local
recurrences [6]. With this new standardized technique, a
unique chance was given to study the effect of (neo)adjuvant
therapy. Based on the good results of preoperative radio-
therapy in Sweden [7], the Dutch Colorectal Cancer Group
started a randomized multicenter trial. They investigated
whether the addition of preoperative radiotherapy increases
the benefit of TME [8–10]. The outcome ofthisstudy showed
a significant reduction in local recurrences with preoperative
radiation compared to operation alone in patients with rectal
cancer(5.6%versus10.2%at6.1years)[11]. Differences were
not significant for tumors in the upper third of the rectum.
Therefore, from the year 2001 onwards, the Comprehensive
Cancer Centre Rotterdam decided to standardize preoperative
radiotherapy for each patient with a tumor up to 10 cm from
the anal verge. A course of 5×5 Gy was given to all these
patients. However, the TME study was performed in selected
patients under optimal conditions and low volume centers
still report higher recurrence rates [12, 13].
This study was designed to assess the outcome after
treatment of primary rectal cancer in a community teaching
hospital with special emphasis on local recurrence and
overall survival.
Materials and methods
Patients and preoperative assessment
Between 1996 and 2003, the hospital charts of 210 patients
with primary rectal cancer were recorded in our prospective
database. Medical records were examined to obtain all
necessary data. All patients had histologically proven
adenocarcinoma of the rectum without evidence of distant
metastases at that stage. The inferior margin of the tumor
was located not further than 15 cm from the anal verge to
be defined as a rectal tumor. Prior to surgery, medical
history, physical examination, and routine blood tests were
assessed. Work-up consisted of colonoscopy with biopsy,
followed by an X-ray of the chest in combination with
abdominal ultrasound to exclude distant metastases. In most
cases, a computed tomography (CT) scan of the abdomen
was also made. In selected cases, especially to rule out the
suspicion of invasion of the tumor into adjacent organs, a
magnetic resonance imaging (MRI) of the pelvis was made.
Our database consists of hospital notes, radiotherapy plans,
operation notes, and histopathological reports to obtain the
following information: demographics, preoperative diag-
nostic intervention, tumor staging, radiotherapy technique,
surgical details, histopathological details, and complica-
tions. Follow-up was registered using hospital notes,
medical letters, and in some cases, by general practitioner
information.
External beam radiation therapy
Starting in 2001, short-term external beam radiation therapy
(EBRT) was given to all patients with a tumor up to 10 cm
[8]. A radiation dose of 25 Gy in five daily fractions was
delivered. In patients with a locally advanced tumor, 50 Gy
radiotherapy was given in 25 daily fractions of 2 Gy.
Locally advanced tumor growth was defined as infiltration
of the tumor in the environment and/or pathologically
enlarged lymph nodes near the circumferential margins of
the mesorectum on a CT scan. Afterwards, an evaluation of
the effect of radiation therapy was done again by CT scan.
When thought feasible, an explorative laparotomy was done
with the intention to do a resection. EBRTwas administered
by a three-field technique, using one posterior and two
lateral ports.
Surgery
All patients underwent surgery according to the TME
principle, as advocated by Heald [3]. In patients with a high
rectal cancer, the mesorectum was divided 5 cm below the
tumor and a partial mesorectal excision was performed.
Surgery was planned 3–5 days after short-term radiothera-
py. For locally advanced or T4 tumors, reevaluation was
done after irradiation. When feasible, the patient was
operated on 5–6 weeks later. Prophylactic intravenous
antibiotics were given at the induction of anesthesia in all
patients. Three well-trained TME surgeons performed all
operations. In case of an anterior resection, a side to end
anastomosis was made using the double stapling technique.
A diversion stoma was made in case of complicated
procedures, a positive leakage test, or incomplete dough-
nuts. Loop ileostomy was the preferred method in these
cases. In case of a positive leakage test, the leakage was
localized and sutured when discovered.
Pathology
The pathologists were trained to identify Circumferential
Resection Margin (CRM), positive nodes, and lateral spread
of tumor according to the protocol of Quirke et al. [14].
Adjuvant therapy
Generally, patients were not treated with adjuvant chemo-
therapy, irrespective of nodal status. After 2005, there was a
924 Int J Colorectal Dis (2009) 24:923–929tendency to give adjuvant chemotherapy in well-
conditioned patients with positive lymph nodes.
Statistics
Local control and overall survival curves were calculated
from the time of TME and were based on the method of
Kaplan and Meier. All statistical analyses were executed in
SPSS. Univariate comparisons of survival end points were
calculated using the log-rank test. Significance was defined
as P<0.05. For multivariate analysis, Cox regression was
used to evaluate prognostic factors.
Results
Patients
A total of 210 patients were operated on with curative
intent. One hundred thirteen (54%) of the patients were
male and 97 (46%) were female with a median age of
70 years (range 40–90 years) The median level of
preoperative CEA was 2.8 (range 0.2–142). Preoperative
characteristics are shown in Table 1. Fifty-three patients
(25%) received preoperative radiotherapy. The majority of
these patients (n=42) received short-term radiotherapy.
Eleven patients were treated with 50 Gy external beam
radiation therapy because of preoperatively defined locally
advanced tumors. Since 2001, due to changing policy in
preoperative radiotherapy, a growing amount of patients
received EBRT. Of the 40 patients (with a tumor below
10 cm) included in this study from 2001, 36 received short-
term radiotherapy.
Surgical results
A low anterior resection (LAR) was done in 145 patients
(69%) and an abdominoperineal resection (APR) in 65
patients (31%). Of the 145 patients with a LAR, a diverting
stoma was made in 26 patients (18%), which was closed in
18 patients. Five patients underwent a local excision of the
tumor (transanal endoscopic microsurgery [TEM]) as initial
treatment before TME was performed. Thirteen patients
(6%) proved to have hepatic metastases during surgery. In
ten of these patients, hepatic metastases were not diagnosed
by ultrasonography or CT during the preoperative work-up,
but discovered during surgery. In the other three patients,
liver metastases were calculated and operated on during a
second time. The median duration of surgery was 110 min
(range 45–210 min) and the median operative blood loss
was 600 mL (range 50–4,000 mL). The median blood loss
was significantly lower in LAR compared to APR, 400
versus 1,000 mL, respectively (P<0.001).
Complications are depicted in Table 2. Postoperative
mortality was 3% (n=6). Twelve patients underwent a
relaparotomy because of abdominal symptoms. During
operation, an anastomotic leakage was found in eight
patients; three patients were treated with a loop ileostomy
and, in five patients, a colostomy was performed after the
removal of the anastomosis. A reanastomosis was per-
formed, after 6 and 9 months, in two of these patients.
Perineal infections were present in 12 patients (18%) after
an APR and treated conservatively. All these 12 patients
had been treated with preoperative radiotherapy.
Pathology
In 199 patients (95%), a microscopic complete resection
was performed (R0). In 11 (5%) patients, the resection was
microscopically incomplete (R1) including four patients
Table 1 Preoperative characteristics
Total Percentage
Symptoms
Blood loss 153 73
Mucus 38 18
Tenesmus 47 22
Diarrhea 44 21
Constipation 35 17
Distance of tumor from anal verge (cm)
≤55 9 2 8
5–10 87 41
10–15 64 31
Table 2 Postoperative complications and reinterventions
Total Percentage
Minor complications
Urinary infection 16 8
Bladder retention 3 1
Wound infection abdominal 17 8
Major complications
Wound infection perineal 12 18
a
Anastomotic leakage 8 5
Intra-abdominal fluid collection without leak 3 1
Reintervention
Abscess drainage 3 1
Relaparotomy 12 6
Permanent colostomy 7 3
Permanent ileostomy 2 1
Temporary ileostomy 3 1
a18% of 65 APRs
Int J Colorectal Dis (2009) 24:923–929 925with a pT4 tumor. In five patients, incompleteness was
related to the distal margin and in six patients because of an
incomplete CRM. The postoperative tumor stage is given in
Table 3. Two patients had no residual disease after TME.
However, these patients had undergone a TEM before TME.
TME was performed because the local excision was irradical
on pathology. One of these patients had a T1 and one a T2
tumor at the initial pathology. Three patients had a carcinoma
in situ. AT1 tumor was seen in 23 patients, a T2 in 63, a T3
in 106, and a T4 tumor in 15 patients. One hundred twenty-
eight patients were node-negative, 45 had metastasis in one
to three regional lymph nodes (N1), and 37 had metastasis in
four or more regional lymph nodes (N2).
Follow-up
The median follow-up was 3.6 years (range 0.4–8.4 years). In
total, 21 patients developed a local recurrence, most of them
(83%) discovered during the first 2 years of follow-up.
Fourteen of 199 patients with a complete resection developed
a local recurrence (7%). Seven of 11 patients with an
incomplete resection developed a local recurrence (64%). A
complete resection versus an incomplete resection was of
significant importance on local control (P<0.001; Fig. 1).
The actuarial overall 3- and 5-year local control rates were
92% and 88%, respectively. Nineteen of the local recurrences
were found in tumors primary located in the lowest two
thirds of the rectum. A high level of CEA (>5), an APR
(Fig. 2), positive lymph nodes, and an incomplete resection
negatively influenced the local recurrence rate significantly.
There was no significant difference in age, gender, and
preoperative radiotherapy regarding local recurrence (see
Table 4). The significant prognostic factors were entered in a
multivariate analysis (see Table 5). The most important
factor was completeness of the resection. CEA in this
multivariate analysis was not of significant importance
anymore.
Distant metastases
Forty-five patients developed distant metastases, of which
40% was discovered during the first year of follow-up.
Thirty-four patients developed hepatic metastases, 18 lung
metastases, and five bone metastases. Lung and/or bone
metastases were in 38% synchronic with hepatic metastases.
Overall survival
The actuarial overall 3- and 5-year survival rates were 72%
and 58%, respectively. The 5-year overall survival demon-
strated a statistically significant difference between the
pathological TNM (pTNM) stages, type of resection, lymph
nodes, CEA levels (Fig. 3), age, and completeness of the
resection (see Table 4). Patient's gender and preoperative
radiotherapy were not of statistic significance. Increased
age, advanced T stage, positive lymph node status,
increased CEA, and completeness of the resection were
independent risk factors for overall survival in the multi-
variate analysis (see Table 5). In a Cox regression model,
age was the most important factor.
Discussion
Since the introduction of TME as the standard operative
technique, the rate of local recurrence after resection of
Table 3 Pathology
Total Percentage
Residual tumor
R0 199 95
R1 11 58
AJCC pTNM stage
CIS 3 1
I6 7 3 3
II 53 25
III 74 35
IV 13 6
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Fig. 1 Local recurrence according to a complete versus an incomplete
resection (P<0.01)
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Fig. 2 Local recurrence according to type of resection (P<0.01)
926 Int J Colorectal Dis (2009) 24:923–929rectal carcinomas spectacularly decreased from 37% in the
early 1980s after conventional surgery to <10% at present
[5]. TME provides sharp meticulous dissection to keep the
visceral layer of the pelvic fascia intact and this is important
to avoid breach in the mesorectum, which is now an
important cause for local recurrence [15–18]. Neoadjuvant
radiotherapy demonstrated to improve the TME results with
a decreased local recurrence rate, but without an impact on
survival [11]. In the present study, this impact of radiother-
apy on local recurrence was not demonstrated, but the
number of patients is small.
To define the value of TME in a general hospital
population, we decided to include all patients of all ages
with a potentially resectable rectal carcinoma. Evaluation of
the results, therefore, includes patients previously treated by
local transanal resection and patients with postoperatively
proven T4 tumors and elderly patients or patients who are
not fit enough to enter clinical trials. Bearing this in mind,
our results are encouraging. The local recurrence rate was
13% in the whole group at 5 years, including patients with
and without preoperative radiotherapy. When considering
the microscopically complete resected tumors, the recur-
rence rate was 9%. R1 resections showed a 21% local
recurrence rate, which is similar to what has been described
in the literature [17, 19]. Adequate surgery plays a key role
in preventing local recurrences [20, 21]. Quirke showed a
linear correlation between the development of a local
recurrence and an inadequate resection with positive
circumferential margins [14, 22]. It is, therefore, of crucial
importance to optimize preoperative work-up to identify
those patients who will need preoperative treatment in order
to downsize and downstage the tumor. In our study, four
patients with a local recurrence proved to have T4 tumors,
which were not preoperatively correctly diagnosed and,
therefore, did not undergo preoperative chemoradiotherapy.
New imaging techniques using MRI to stage these tumors
accurately will improve this in the future [23–27].
The use of sharp perimesorectal dissection and the
practice of “close shave” anterior resection has not only
led to fewer recurrences but also increased the sphincter
saving rate. Heald et al. [28] reported that APR was
required in 23% of patients with tumors in the lower
rectum. In the present study, an APR was performed in 30%
Local recurrence Overall survival
HR 95%CI P value HR 95%CI P value
Type of resection—APR 0.20 0.1–0.5 0.000 0.74 0.4–1.2 0.284
Lymph nodes—positive 3.63 1.5–8.9 0.005 1.99 1.2–3.3 0.007
Completeness—incomplete 0.00 0.00–100+ 0.000 1.01 0.4–2.5 0.981
Level of CEA—>5 2.05 0.8–4.9 0.105 1.83 1.1–3.0 0.019
Age—>80 –– – 2.76 1.5–5.0 0.000
Table 5 Results of the
multivariate Cox regression
analysis for local recurrence and
overall survival
HR hazard ratio, 95%CI 95%
confidence interval
Table 4 Univariate analysis on 5-year local recurrence-free (LRF)
and overall survival (OS)
Number LRF (%) P value OS (%) P value
Radiotherapy 0.32 0.17
Yes 53 82 67
No 157 93 55
Type of resection
LAR 145 93 <0.01 61 0.02
APR 65 63 50
CEA 0.05 0.04
<5 151 90 65
>5 59 65 48
Male 114 90 0.55 57 0.60
Female 96 85 55
Age 0.36 <0.01
<80 173 85 64
>80 37 75 30
Node <0.01 0.01
Negative 82 93 65
Positive 128 79 34
Extent of resection
Complete 199 92 <0.01 62 0.05
Incomplete 11 20 17
Tumor height (cm) 0.11 0.23
0–55 9 8 2 5 2
5–10 87 85 56
10–15 64 95 65
0%
25%
50%
75%
100%
012345
Years after surgery
P
a
t
i
e
n
t
 
S
u
r
v
i
v
a
l
CEA
CEA
N=151 
N=59
P=0.04
<5 
>5 
Fig. 3 Overall survival according to CEA (P=0.04)
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on both local control and overall survival and the high rate
of perineal complications in patients with an APR pre-
treated with preoperative radiotherapy, it is favorable to
have fewer APR [8].
Anastomotic leakage is a major complication associated
with TME. As the risk of leakage depends on the level of the
anastomosis, the incidence of leakage is high following TME
in low rectal tumors (7–9%) [29]. A total of eight patients
(5%) in our study developed an anastomotic leakage. Six of
them (75%) were located in patients with very low anasto-
moses (below 5 cm), which increases the risk for leakage. All
thesepatientshadbeentreatedwithpreoperativeradiotherapy,
which is known to increase the risk for leakage [30–32].
The prognosis in our patient series is similar to other
reported data, showing an overall survival of more than
60% after 5 years [33, 34]. To identify prognostic factors, a
univariate analysis was included. As expected, TNM
classification was of significant importance for prognosis
[17]. As reported by many others [8, 11, 13, 35–39],
completeness of the resection was also a significant
prognostic factor. New treatment protocols (neoadjuvant
chemoradiation) and meticulous preoperative work-up will
possibly lead to more complete resections in the future.
Furthermore, in contrast with previous reports [40], high
levels of CEA levels were of significant importance on both
overall survival and local recurrence in the present study
[41–44]. Age >80 was also an important factor for a
decreased overall survival in the present study. After 5 years,
the overall survival of patients above 80 was 30% compared
to 64% in patients under the age of 80. The incidence of
comorbidity, which renders the patient vulnerable to postop-
erative complications, is also highest after this age [45, 46].
After major resectional treatment, elderly patients with rectal
cancer have an increased 30-day and 6-month mortality
compared with younger patients. Treatment-related mortality
is an important competitive risk factor, which obscures the
positive effect of modern rectal cancer treatment in those
aged 75 years and above [37, 46–48].
In conclusion, TME is a feasible technique with an
acceptable rate of postoperative morbidity and low
mortality also in a community hospital. Patients with
positive lymph nodes, an incomplete resection, aged
above 80, and/or a high level of CEA have a poor
prognosis. Meticulous preoperative work-up is of great
importance to decrease incomplete resections and im-
prove results in future patients.
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